423 results about "Susceptibility gene" patented technology

A role of the human PDE4D gene in stroke is disclosed. Methods for diagnosis, prediction of clinical course and treatment for stroke using polymorphisms in the PDE4D gene are also disclosed.

The present invention provides the identification of a number of SNPs that are associated schizophrenia, schizoaffective disorder, bipolar disorder and related mental disorders which were found to be strongly linked to individuals with the disease. The invention provides SNP locations on human chromosome 6, as well as methods of making PCR primers and assays for detecting the SNPs in tested individuals.

Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described.

Linkage of myocardial infarction (MI) and a locus on chromosome 13q12 is disclosed. In particular, the FLAP gene within this locus is shown by genetic association analysis to be a susceptibility gene for MI and ACS, as well as stroke and PAOD. Pathway targeting for treatment and diagnostic applications in identifying those who are at risk of developing MI, ACS, stroke or PAOD, in particular are described. The invention also provides for compositions comprising a leukotriene synthesis inhibitor and a stating and methods of using these compositions to reduce C-reactive protein in a human subject at risk of MI, ACS, stroke and/or PAOD.

The invention relates to a disease risk predication method and system. The method comprises the following steps of: S1, receiving input gene sequencing result information; analyzing the input gene sequencing result information to obtain all mutant gene information; S2, looking up disease gene mutant information of corresponding gene sites from a precision medical knowledge base according to the gene sites corresponding to the mutant gene information, so as to obtain at least one piece of disease gene mutant information; S3, matching each piece of the disease gene mutant information with all the disease gene mutant information to obtain the similarity of each piece of the mutant gene information, and all the disease gene mutant information; and S4, obtaining a risk predication table aiming at the gene sequencing result information according to the similarity of each piece of the mutant gene information, and all the disease gene mutant information. By analyzing an association relation of susceptibility genes, mutation sites, mutation types and diseases, disease risk predication is carried out on healthy people and general disease risk grade predication is provided; disease risks in the future are reduced.

The invention relates to a hereditable deafness susceptibility gene screen test kit. The kit uses mutation from C to T of 1,494 locus of a 12s rRNA gene, mutation from A to G of 1,555 locus of the 12srRNA gene, mutation from A to G of IVS7(-2) locus of an SLC26A4 gene and C(+/-) of 235 locus of a GJB2 gene as detecting objects, designs and optimizes a set of specific primers respectively againsteach locus to be tested according to the PCR technical principle of a tetra-primer amplification refractory mutation system, amplifies the whole set of the primers in the same reaction tube, and performs primary multiple PCR amplification and primary gel electrophoresis on the four reaction tubes to obtain gene types of four loci simultaneously.

The invention provides a probe set and a reagent kit used for detecting pathopoiesia/susceptibility genes of congenital megacolon and relative syndromes. At most 172 pathopoiesia/susceptibility genes related to diseases can be detected at the same time, and reference can be provided for affected individual molecular genetics diagnosis, mass survey of congenital megacolon high-incidence areas, screening of high-risk affected groups in congenital megacolon family members and corresponding genetic counseling or prenatal intervention.

The invention provides a non-invasive detection kit for detecting susceptible genes of women osteoporosis. The kit comprises five osteoporosis single nucleotide polymorphism genotype specific primers, a DNA sequencing primer, a polymerase chain reaction (PCR) reaction component, a PCR product purification component, a DNA sequencing reaction component and the like, wherein the five osteoporosis single nucleotide polymorphism genotype specific primers are used for detecting G-174C on an IL-6 gene, BsmI and TaqI on a VDR gene, G-308A on a TNF-a and Lys3Asn on an OPG gene. The kit can screen out high-risk women group susceptible to osteoporosis by detecting the genotypes of the five osteoporosis single nucleotide polymorphisms closely related to osteoporosis, can evaluate the risk level susceptible to osteoporosis from gene level according to the gene detection result of every checked person and can guide menopausal women to effectively prevent osteoporosis.

Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed.

The invention belongs to the field of molecular biology and medicine, relating to a method for detecting a hypertension susceptibility gene and a detection kit thereof. The method for detecting a primary hypertension susceptibility gene comprises the following step of: detecting the genotype of the rs2295281 locus of a mitochondrion fusion gene 2(Mfn2)/a hyperplasia suppressor gene (HSG). The hypertension susceptibility of an rs2295281 individual with a genotype C is remarkably higher than that of the general public. The invention also discloses the corresponding detection kit. The detection kit contains a primer for amplifying the rs2295281 locus and can also contain the primer for amplifying a region comprising the rs2295281 locus in an eighth intron of the Mfn2 gene. The genotype of the rs2295281 locus is detected by adopting the method. The invention has simple and easy method, quick speed and high efficiency and low cost and provides a novel shortcut approach for diagnosing and treating hypertension.

The invention belongs to the molecular biology and medicine field and relates to a method for detecting a susceptibility gene of hypertension and a detection kit thereof. The invention provides a method for detecting a susceptibility gene of essential hypertension, comprising the step of detecting the genetype of a mitochondrion fusion gene 2(Mfn2)/hyperplasia suppressor gene (HSG) locus rs2336384. The individual, rs2336384 of which carries the G genetype has obviously higher susceptibility of hypertension than the common people. The invention also discloses the corresponding detection kit which contains a primer amplifying the locus rs2336384 and a primer amplifying the region of the locus rs2336384 contained in the No.2 intron of the Mfn2 gene. Being used for detecting the genetype of the locus rs2336384, the method is simple and practicable, fast and efficient and low in cost and provides a simple and direct new way for hypertension diagnosis and treatment.

The invention relates to a method for acquiring characterization parameters of hypertension and complication. The method comprises the following steps of: 1) establishing a hypertension and complication susceptibility gene database; 2) constructing an individual hypertension and complication characterization parameter analysis platform according to the hypertension and complication susceptibility gene database established in the step (1); 3) analyzing individual hypertension and complication characterization parameters based on the analysis platform constructed in the step (2); and 4) outputting individual hypertension and complication characterization parameters. The invention provides a method for acquiring the hypertension and complication characterization parameters which can acquire accurate characterization information, can acquire the information timely and can lay a foundation for follow-up treatment work.

The invention relates to the field of genetic engineering, and provides a method and a kit for assaying breast cancer susceptibility genes. The method for assaying breast cancer susceptibility genes includes the following steps: (A) breast cancer susceptibility gene specific primers are utilized to amplify a plurality of target regions in a sample to be assayed, and a sequencing library is constructed on the basis of amplification products; (B) the single-molecule amplification of the sequencing library is carried out, so that a plurality of single-molecule amplification products corresponding to the target regions are obtained; (C) the high-throughput gene sequencing of the single-molecule amplification products is carried out simultaneously, so that the sequence information of the target regions is obtained. The method and the kit for assaying breast cancer, which are provided by the invention, can assay a plurality of regions of a breast cancer susceptibility gene at the same time, consequently, the efficiency of assay is increased, the assay cost is reduced, and in addition, the sensitivity of assay and the comprehensiveness and accuracy of the assay result are increased as well.

The invention discloses a kit for detecting deafness susceptibility genes, namely the invention provides a kit for rapidly and accurately detecting the GJB2, SLC26A4 and 12SrRNA deafness susceptibility genes by virtue of an MALDI-TOF mass-spectrometry technique. The kit mainly consists of the following ingredients: PCR amplification products shown as SEQ ID NO:1-SEQ ID NO:32 and mass-spectrometry extension primers shown as SEQ ID NO:33-SEQ ID NO:48. The kit provided by the invention, by combining the mass-spectrometry technique and a multi-primer extension technique, is relatively simple in adopted reagent consumables, low in cost and stable, and dozens to thousands of samples are analyzed in one reaction, so that loss caused by reagent preparation is reduced; and the kit is quite high in sensitivity, accuracy and detection consistency, and detection throughput is improved.

The invention provides a probe group for detecting pathogenic/susceptible genes of hereditary cardiomyopathy/arrhythmia, and provides application of a reagent for detecting pathogenic and/or susceptible genes of the cardiomyopathy in preparing products for diagnosing the cardiomyopathy. The reagent can capture various pathogenic and/or susceptible genes of the cardiomyopathy, and at most 312 related genes can be detected simultaneously. The invention further provides a probe group for detecting the pathogenic and/or susceptible genes of the cardiomyopathy and a kit containing the probe group.The probe group and the kit containing the probe group can be used for molecular genetic diagnosis of a sick individual and family screening of the sick family members, and have important clinical significance to early intervening treatment of the mutation carriers. Meanwhile, the probe group and the kit have the advantages of being high in efficiency, multiple in detection sites, accurate, easy to operate, good in specificity, high in sensitivity, rapid, high in practicability and low in cost.

The invention relates to the field of gene detection, and particularly relates to a kit and method for detecting an aminoglycoside drug-induced deafness-sensitive gene through a fluorescent PCR (polymerase chain reaction)-melting curve method. The technical scheme of the invention provides a kit for detecting an aminoglycoside drug-induced deafness-sensitive gene. The kit comprises a PCR solution, a negative quality control sample and a positive quality control sample, wherein the PCR solution comprises primers, a PCR Buffer, a dNTP (deoxyribonucleotide triphosphate) mixed solution, saturated fluorescent dyes, a Taq enzyme and a UNG enzyme. In the invention, the specific PCR primers are designed according to SNP (single nucleotide polymorphism) sites of the aminoglycoside drug-induced deafness-sensitive gene, two aminoglycoside drug-induced deafness-sensitive sites can be detected in one PCR, the operation can be finished in one tube, and the detection is quick, accurate and wide in range.

The invention provides a method for detecting pathogenic genes of other system diseases causing cardiovascular symptoms, and provides application of a reagent for detecting pathogenic and/or susceptible genes of other systemic diseases causing cardiovascular symptoms in preparing products for diagnosing other systemic diseases causing the cardiovascular symptoms. The reagent can detect at most 263diseases related genes simultaneously, and a reference can be provided for genetic diagnosis and personalized treatment of sick individuals so as to study causes of other systemic diseases causing the cardiovascular symptoms and to assess risk factors for early intervention and early treatment.